

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVERGRANDE HEALTH  
INDUSTRY GROUP**

**EVERGRANDE HEALTH INDUSTRY GROUP LIMITED**

**恒大健康產業集團有限公司**

*(a company incorporated in Hong Kong with limited liability)*

**(Stock code: 708)**

### **PROFIT WARNING**

This announcement is made by Evergrande Health Industry Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**shareholders**”) and potential investors that, based on the information currently available to the management, the Group is expected to record net loss for the year ended 31 December 2018 (“**2018**”) of approximately RMB1.4 billion, whereas the net profit of the Company for the year ended 31 December 2017 (“**2017**”) was approximately RMB300 million. The Company expects the net loss is primarily attributable to the following factors:

- (a) the performance of the health management segment of the Group is expected to be stable, and the net profit recorded for 2018 is expected to be similar to that of 2017; and
- (b) the new energy vehicle segment of the Group is expected to record a net loss in 2018 of approximately RMB1.7 billion, as the Group has accounted for losses in its investment in Smart King Ltd. (an associate of the Group) in 2018 through the equity accounting method, incurred interest expense in respect of the relevant loans and other expenses.

The information contained in this announcement is only a preliminary assessment by the management of the Company and is not based on any figures or information which has been audited or reviewed by the Company’s auditor or the audit committee of the Board. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for 2018, which is expected to be published by the end of March 2019.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Evergrande Health Industry Group Limited**  
**Shi Shouming**  
*Chairman*

Hong Kong, 5 March 2019

*As at the date of this announcement, the executive Directors of the Company are Mr. SHI Shouming, Mr. PENG Jianjun and Mr. QIN Liyong; and the independent non-executive Directors of the Company are Mr. CHAU Shing Yim David, Mr. GUO Jianwen and Mr. XIE Wu.*